These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34110834)

  • 1. Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.
    Freeman-Cook KD; Hoffman RL; Behenna DC; Boras B; Carelli J; Diehl W; Ferre RA; He YA; Hui A; Huang B; Huser N; Jones R; Kephart SE; Lapek J; McTigue M; Miller N; Murray BW; Nagata A; Nguyen L; Niessen S; Ninkovic S; O'Doherty I; Ornelas MA; Solowiej J; Sutton SC; Tran K; Tseng E; Visswanathan R; Xu M; Zehnder L; Zhang Q; Zhang C; Dann S
    J Med Chem; 2021 Jul; 64(13):9056-9077. PubMed ID: 34110834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma.
    Yuan K; Kuang W; Chen W; Ji M; Min W; Zhu Y; Hou Y; Wang X; Li J; Wang L; Yang P
    Eur J Med Chem; 2022 Jan; 228():114024. PubMed ID: 34875521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
    Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
    Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Han Y; Xiao W; Wang Z; Shi W; Mao Y; Yu J; Xia G; Liu Y
    Eur J Med Chem; 2019 Sep; 178():352-364. PubMed ID: 31200237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.
    Fu Y; Tang S; Su Y; Lan X; Ye Y; Zha C; Li L; Cao J; Chen Y; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5332-5336. PubMed ID: 29074254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Wang Z; Shi W; Mao Y; Yu J; Ke Y; Xia G
    Eur J Med Chem; 2020 May; 193():112239. PubMed ID: 32200202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening.
    Yuan K; Min W; Wang X; Li J; Kuang W; Zhang F; Xie S; Yang P
    Future Med Chem; 2020 Jun; 12(12):1121-1136. PubMed ID: 32400188
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
    Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
    El-Naggar AM; El-Hashash MA; Elkaeed EB
    Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
    Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
    J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.
    Huang Z; Zhao B; Qin Z; Li Y; Wang T; Zhou W; Zheng J; Yang S; Shi Y; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111541. PubMed ID: 31382120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities.
    Liang JW; Li WQ; Nian QY; Xie SH; Yang L; Meng FH
    Bioorg Chem; 2022 Feb; 119():105547. PubMed ID: 34906858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.
    Zhao H; Hu X; Cao K; Zhang Y; Zhao K; Tang C; Feng B
    Eur J Med Chem; 2018 Sep; 157():935-945. PubMed ID: 30165341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies.
    Guan H; Du Y; Han W; Shen J; Li Q
    Anticancer Agents Med Chem; 2017; 17(5):646-657. PubMed ID: 28044938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of colchicine aryne cycloadduct as a potent molecule for the abrogation of epithelial to mesenchymal transition via modulating cell cycle regulatory CDK-2 and CDK-4 kinases in breast cancer cells.
    Iqbal Lone W; Chand J; Kumar P; Garg Y; Ahmed Z; Mukherjee D; Goswami A; Momo H Anãl J
    Bioorg Chem; 2024 Sep; 150():107581. PubMed ID: 38908129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.
    Xu J; Li H; Wang X; Huang J; Li S; Liu C; Dong R; Zhu G; Duan C; Jiang F; Zhang Y; Zhu Y; Zhang T; Chen Y; Tang W; Lu T
    Eur J Med Chem; 2020 Aug; 200():112424. PubMed ID: 32447197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.